160 research outputs found
ARTEMIS Mission Overview: From Concept to Operations
ARTEMIS (Acceleration, Reconnection, Turbulence and Electrodynamics of the Moon's Interaction with the Sun) repurposed two spacecraft to extend their useful science (Angelopoulos, 2010) by moving them via lunar gravity assists from elliptical Earth orbits to L1 and L2 Earth-Moon libration orbits and then to lunar orbits by exploiting the Earth-Moon-Sun dynamical environment. This paper describes the complete design from conceptual plans using weak stability transfer options and lunar gravity assist to the implementation and operational support of the Earth-Moon libration and lunar orbits. The two spacecraft of the ARTEMIS mission will have just entered lunar orbit at this paper's presentation
Supporting Primary Source Instruction in the Undergraduate Classroom at Bowling Green State University: Summary Findings
This report presents the findings and recommendations of research conducted as a part of a study on Teaching with Primary Sources at Bowling Green State University (BGSU) during the Fall 2019 semester. It is worthy to note that this research project was conducted prior to the COVID outbreak. Along with a cohort of over two dozen institutions as part of a national study coordinated by Ithaka S+R, members of the BGSU library faculty conducted this local study with faculty who teach undergraduates with primary sources in the classroom. This report draws only on interviews conducted at BGSU.
After describing the methodology employed, this report will present our findings covering four major themes identified in interviews: difficulties with primary sources, learning to work with primary sources, the role of librarians and archivists in primary source projects, and connections to information literacies. The report concludes with recommendations
Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study
Background: Acute hepatic porphyria (AHP) is a family of four rare genetic diseases, each involving deficiency in
a hepatic heme biosynthetic enzyme. Resultant overproduction of the neurotoxic intermediates δ-aminolevulinic
acid (ALA) and porphobilinogen (PBG) leads to disabling acute neurovisceral attacks and progressive neuropathy.
We evaluated the AHP disease burden in patients aged ≥ 12 years in a post hoc analysis of the Phase 3, randomized,
double-blind, placebo-controlled ENVISION trial of givosiran (NCT03338816), an RNA interference (RNAi) therapeutic
that targets the enzyme ALAS1 to decrease ALA and PBG production. We analyzed baseline AHP severity via chronic
symptoms between attacks, comorbidities, concomitant medications, hemin-associated complications, and quality
of life (QOL) and evaluated givosiran (2.5 mg/kg monthly) in patients with and without prior hemin prophylaxis on
number and severity of attacks and pain scores during and between attacks.
Results: Participants (placebo, n = 46; givosiran, n = 48) included patients with low and high annualized attack rates
(AARs; range 0–46). At baseline, patients reported chronic symptoms (52%), including nausea, fatigue, and pain;
comorbidities, including neuropathy (38%) and psychiatric disorders (47%); concomitant medications, including
chronic opioids (29%); hemin-associated complications (eg, iron overload); and poor QOL (low SF-12 and EuroQol
visual analog scale scores). A linear relationship between time since diagnosis and AAR with placebo suggested worsening
of disease over time without effective treatment. Givosiran reduced the number and severity of attacks, days
with worst pain scores above baseline, and opioid use versus placebo.
Conclusions: Patients with AHP, regardless of annualized attack rates, have considerable disease burden that may partly be alleviated with givosiran
Novel Compound Heterozygous Mutations Expand the Recognized Phenotypes of \u3cem\u3eFARS2\u3c/em\u3e-linked Disease
Mutations in mitochondrial aminoacyl-tRNA synthetases are an increasingly recognized cause of human diseases, often arising in individuals with compound heterozygous mutations and presenting with system-specific phenotypes, frequently neurologic. FARS2 encodes mitochondrial phenylalanyl transfer ribonucleic acid (RNA) synthetase (mtPheRS), perturbations of which have been reported in 6 cases of an infantile, lethal disease with refractory epilepsy and progressive myoclonus. Here the authors report the case of juvenile onset refractory epilepsy and progressive myoclonus with compound heterozygous FARS2 mutations. The authors describe the clinical course over 6 years of care at their institution and diagnostic studies including electroencephalogram (EEG), brain magnetic resonance imaging (MRI), serum and cerebrospinal fluid analyses, skeletal muscle biopsy histology, and autopsy gross and histologic findings, which include features shared with Alpers-Huttenlocher syndrome, Leigh syndrome, and a previously published case of FARS2 mutation associated infantile onset disease. The authors also present structure-guided analysis of the relevant mutations based on published mitochondrial phenylalanyl transfer RNA synthetase and related protein crystal structures as well as biochemical analysis of the corresponding recombinant mutant proteins
EXPLORE B : A prospective, long-term natural history study of patients with acute hepatic porphyria with chronic symptoms
One-year data from EXPLORE Part A showed high disease burden and impaired quality of life (QOL) in patients with acute hepatic porphyria (AHP) with recurrent attacks. We report baseline data of patients who enrolled in EXPLORE Part B for up to an additional 3 years of follow-up. EXPLORE B is a long-term, prospective study evaluating disease activity, pain intensity, and QOL in patients with AHP with >= 1 attack in the 12 months before enrollment or receiving hemin or gonadotropin-releasing hormone prophylaxis. Data were evaluated in patients with more (>= 3 attacks or on prophylaxis treatment) or fewer (= 80% of patients; most received hemin during attacks. Almost three-quarters of patients reported chronic symptoms between attacks, including 85% of patients with fewer attacks. Pain intensity was comparable among both attack subgroups; most patients required pain medication. All groups had diminished QOL on the EuroQol visual analog scale and the European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 versus population norms. Patients with AHP with recurrent attacks, even those having fewer attacks, experience a high disease burden, as evidenced by chronic symptoms between attacks and impaired QOL.Peer reviewe
Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial
BACKGROUND: Primary hyperoxaluria type 1 (PH1) is a rare genetic disease that causes progressive kidney damage and systemic oxalosis due to hepatic overproduction of oxalate. Lumasiran demonstrated efficacy and safety in the 6-month primary analysis period of the phase 3, multinational, open-label, single-arm ILLUMINATE-B study of infants and children < 6 years old with PH1 (ClinicalTrials.gov: NCT03905694 (4/1/2019); EudraCT: 2018–004,014-17 (10/12/2018)). Outcomes in the ILLUMINATE-B extension period (EP) for patients who completed ≥ 12 months on study are reported here. METHODS: Of the 18 patients enrolled in the 6-month primary analysis period, all entered the EP and completed ≥ 6 additional months of lumasiran treatment (median (range) duration of total exposure, 17.8 (12.7–20.5) months). RESULTS: Lumasiran treatment was previously reported to reduce spot urinary oxalate:creatinine ratio by 72% at month 6, which was maintained at 72% at month 12; mean month 12 reductions in prespecified weight subgroups were 89%, 68%, and 71% for patients weighing < 10 kg, 10 to < 20 kg, and ≥ 20 kg, respectively. The mean reduction from baseline in plasma oxalate level was reported to be 32% at month 6, and this improved to 47% at month 12. Additional improvements were also seen in nephrocalcinosis grade, and kidney stone event rates remained low. The most common lumasiran-related adverse events were mild, transient injection-site reactions (3 patients (17%)). CONCLUSIONS: Lumasiran treatment provided sustained reductions in urinary and plasma oxalate through month 12 across all weight subgroups, with an acceptable safety profile, in infants and young children with PH1. GRAPHICAL ABSTRACT: A higher resolution version of the Graphical abstract is available as Supplementary information
Efficacy and safety of givosiran for acute hepatic porphyria: Final results of the randomized phase III ENVISION trial
Background & Aims: Acute hepatic porphyria (AHP) is caused by defects in hepatic
heme biosynthesis, leading to disabling acute neurovisceral attacks and chronic
symptoms. In ENVISION (NCT03338816), givosiran treatment for 6 months reduced
attacks and other disease manifestations, compared with placebo. Here we report data
from the 36-month final analysis of ENVISION.
Methods: Ninety-four patients with AHP (age ≥12 years) and recurrent attacks were
randomized 1:1 to monthly double-blind subcutaneous givosiran 2.5 mg/kg (N=48) or
placebo (N=46) for 6 months. In the open-label extension (OLE) period, 93 patients
received givosiran 2.5 or 1.25 mg/kg for 6 months or more before transitioning to 2.5
mg/kg. Endpoints were exploratory unless otherwise noted.
Results: During givosiran treatment, median annualized attack rate (AAR) was 0.4.
Through Month 36, annualized days of hemin use remained low in the continuous
givosiran group (median, 0.0 to 0.4) and decreased in the placebo crossover group
(16.2 to 0.4). At end of OLE, in the continuous givosiran and placebo crossover groups,
86% and 92%, respectively, had 0 attacks. AAR was lower than historical AAR in 98%
and 100%, respectively (post hoc analysis), and there were 0 days of hemin use in 88%
and 90%, respectively. The 12-item Short Form Health Survey physical and mental
component scores increased by 8.6 and 8.1, respectively (continuous givosiran) and 9.4
and 3.2, respectively (placebo crossover). EQ-5D health-related questionnaire scores
increased by 18.9 (continuous givosiran) and 9.9 (placebo crossover). Lowering of
urinary delta-aminolevulinic acid and porphobilinogen levels was sustained. Safety
findings demonstrated a continued positive risk/benefit profile for givosiran
Disease Burden in Patients with Acute Hepatic Porphyria: Experience from the Phase 3 ENVISION Study
BACKGROUND: Acute hepatic porphyria (AHP) is a family of four rare genetic diseases, each involving deficiency in a hepatic heme biosynthetic enzyme. Resultant overproduction of the neurotoxic intermediates δ-aminolevulinic acid (ALA) and porphobilinogen (PBG) leads to disabling acute neurovisceral attacks and progressive neuropathy. We evaluated the AHP disease burden in patients aged ≥ 12 years in a post hoc analysis of the Phase 3, randomized, double-blind, placebo-controlled ENVISION trial of givosiran (NCT03338816), an RNA interference (RNAi) therapeutic that targets the enzyme ALAS1 to decrease ALA and PBG production. We analyzed baseline AHP severity via chronic symptoms between attacks, comorbidities, concomitant medications, hemin-associated complications, and quality of life (QOL) and evaluated givosiran (2.5 mg/kg monthly) in patients with and without prior hemin prophylaxis on number and severity of attacks and pain scores during and between attacks.
RESULTS: Participants (placebo, n = 46; givosiran, n = 48) included patients with low and high annualized attack rates (AARs; range 0-46). At baseline, patients reported chronic symptoms (52%), including nausea, fatigue, and pain; comorbidities, including neuropathy (38%) and psychiatric disorders (47%); concomitant medications, including chronic opioids (29%); hemin-associated complications (eg, iron overload); and poor QOL (low SF-12 and EuroQol visual analog scale scores). A linear relationship between time since diagnosis and AAR with placebo suggested worsening of disease over time without effective treatment. Givosiran reduced the number and severity of attacks, days with worst pain scores above baseline, and opioid use versus placebo.
CONCLUSIONS: Patients with AHP, regardless of annualized attack rates, have considerable disease burden that may partly be alleviated with givosiran
Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study
Background & Aims
Upregulation of hepatic delta-aminolevulinic acid synthase 1 with accumulation of potentially toxic heme precursors delta-aminolevulinic acid and porphobilinogen is fundamental to the pathogenesis of acute hepatic porphyria. Aims: evaluate long-term efficacy and safety of givosiran in acute hepatic porphyria.
Methods
Interim analysis of ongoing ENVISION study (NCT03338816), after all active patients completed their Month 24 visit. Patients with acute hepatic porphyria (≥12 years) with recurrent attacks received givosiran (2.5 mg/kg monthly) (n=48) or placebo (n=46) for 6 months (double-blind period); 93 received givosiran (2.5 mg or 1.25 mg/kg monthly) in the open-label extension (continuous givosiran, n=47/48; placebo crossover, n=46/46). Endpoints included annualized attack rate, urinary delta-aminolevulinic acid and porphobilinogen levels, hemin use, daily worst pain, quality of life, and adverse events.
Results
Patients receiving continuous givosiran had sustained annualized attack rate reduction (median 1.0 in double-blind period, 0.0 in open-label extension); in placebo crossover patients, median annualized attack rate decreased from 10.7 to 1.4. Median annualized days of hemin use were 0.0 (double-blind period) and 0.0 (open-label extension) for continuous givosiran patients and reduced from 14.98 to 0.71 for placebo crossover patients. Long-term givosiran led to sustained lowering of delta-aminolevulinic acid and porphobilinogen and improvements in daily worst pain and quality of life. Safety findings were consistent with the double-blind period.
Conclusions
Long-term givosiran has an acceptable safety profile and significantly benefits acute hepatic porphyria patients with recurrent attacks by reducing attack frequency, hemin use, and severity of daily worst pain while improving quality of life
Recommended from our members
An integrated clinical program and crowdsourcing strategy for genomic sequencing and Mendelian disease gene discovery.
Despite major progress in defining the genetic basis of Mendelian disorders, the molecular etiology of many cases remains unknown. Patients with these undiagnosed disorders often have complex presentations and require treatment by multiple health care specialists. Here, we describe an integrated clinical diagnostic and research program using whole-exome and whole-genome sequencing (WES/WGS) for Mendelian disease gene discovery. This program employs specific case ascertainment parameters, a WES/WGS computational analysis pipeline that is optimized for Mendelian disease gene discovery with variant callers tuned to specific inheritance modes, an interdisciplinary crowdsourcing strategy for genomic sequence analysis, matchmaking for additional cases, and integration of the findings regarding gene causality with the clinical management plan. The interdisciplinary gene discovery team includes clinical, computational, and experimental biomedical specialists who interact to identify the genetic etiology of the disease, and when so warranted, to devise improved or novel treatments for affected patients. This program effectively integrates the clinical and research missions of an academic medical center and affords both diagnostic and therapeutic options for patients suffering from genetic disease. It may therefore be germane to other academic medical institutions engaged in implementing genomic medicine programs
- …